Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 9/20 | 0.34 |
| ▸ | USP8 | P40818 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19160429 | 0.85 | CA1 (0.35) | CA1CA2CA7CA9MAOB | |
| SCHEMBL5636813 | 0.78 | S100A4 (0.41) | USP8USP7USP47ACHEPARP1 | |
| SCHEMBL8534521 | 0.78 | CASP1 (0.43) | CA9 | |
| SCHEMBL2627985 | 0.74 | ENPP2 (0.33) | CA1CA2 | |
| SCHEMBL22715669 | 0.73 | MAPKAPK2 (0.39) | MAOB | |
| SCHEMBL2993068 | 0.73 | PTPRC (0.47) | CA1CA2CA7CA9ACHE | |
| SCHEMBL31116 | 0.72 | MEN1 (0.35) | MAOB | |
| SCHEMBL8671968 | 0.72 | HTR5A (0.34) | ACHEPARP1PARP10 | |
| SCHEMBL28580991 | 0.71 | HTR2A (0.38) | CA1CA2CA7CA9USP8 | |
| Fluoride SCHEMBL4741377 | 0.71 | MEN1 (0.33) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210114993-A1 | COMPOUNDS FOR TREATING ILK-MEDIATED DISEASES | THE CLEVELAND CLINIC FOUNDATION | 2021-04-22 | — | — | US | disclosed |
| EP-0990647-B1 | PROCESS FOR PRODUCING QUINOLONE DERIVATIVES | KIRIN BREWERY (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-6187926-B1 | REACTING ORTHO-AMINOACETOPHENONE DERIVATIVE WITH FORMIC ACID ESTER IN APROTIC SOLVENT IN PRESENCE OF BASE, ADDING PROTIC SOLVENT TO REACTION MIXTURE | KIRIN BEER KABUSHIKI KAISHA (JP) | 2001-02-13 | — | — | US | disclosed |
| EP-0990647-A1 | PROCESS FOR PRODUCING QUINOLONE DERIVATIVES | KIRIN BEER KABUSHIKI KAISHA (JP) | 2000-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210114993-A1 | COMPOUNDS FOR TREATING ILK-MEDIATED DISEASES | ILK, ITGB1, ITGA2B | CA1 3520/4885CA2 3204/4885CA7 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.